Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction

被引:325
|
作者
Zhao, Ende [1 ,2 ]
Maj, Tomasz [1 ]
Kryczek, Ilona [1 ]
Li, Wei [1 ,2 ]
Wu, Ke [1 ,2 ]
Zhao, Lili [3 ]
Wei, Shuang [1 ]
Crespo, Joel [1 ]
Wan, Shanshan [1 ]
Vatan, Linda [1 ]
Szeliga, Wojciech [1 ]
Shao, Irene [1 ]
Wang, Yin [1 ]
Liu, Yan [1 ]
Varambally, Sooryanarayana [4 ,5 ]
Chinnaiyan, Arul M. [5 ]
Welling, Theodore H. [1 ]
Marquez, Victor [6 ]
Kotarski, Jan [7 ]
Wang, Hongbo [8 ]
Wang, Zehua [8 ]
Zhang, Yi [9 ]
Liu, Rebecca [10 ]
Wang, Guobin
Zou, Weiping [1 ,11 ,12 ]
机构
[1] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Surg, Wuhan 430074, Peoples R China
[3] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI USA
[4] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[5] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[6] NCI, Ctr Canc Res, Biol Chem Lab, Frederick, MD 21701 USA
[7] Med Univ Lublin, Dept Gynecol Oncol & Gynecol 1, Lublin, Poland
[8] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China
[9] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA
[10] Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI USA
[11] Univ Michigan, Grad Programs Immunol & Canc Biol, Ann Arbor, MI 48109 USA
[12] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
HISTONE METHYLTRANSFERASE EZH2; GROUP PROTEIN EZH2; TH17; CELLS; SURVIVAL; EXPRESSION; STEMNESS; DIFFERENTIATION; METHYLATION; REPRESSION; INHIBITOR;
D O I
10.1038/ni.3313
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aerobic glycolysis regulates T cell function. However, whether and how primary cancer alters T cell glycolytic metabolism and affects tumor immunity in cancer patients remains a question. Here we found that ovarian cancers imposed glucose restriction on T cells and dampened their function via maintaining high expression of microRNAs miR-101 and miR-26a, which constrained expression of the methyltransferase EZH2. EZH2 activated the Notch pathway by suppressing Notch repressors Numb and Fbxw7 via trimethylation of histone H3 at Lys27 and, consequently, stimulated T cell polyfunctional cytokine expression and promoted their survival via Bcl-2 signaling. Moreover, small hairpin RNA-mediated knockdown of human EZH2 in T cells elicited poor antitumor immunity. EZH2(+)CD8(+) T cells were associated with improved survival in patients. Together, these data unveil a metabolic target and mechanism of cancer immune evasion.
引用
收藏
页码:95 / +
页数:11
相关论文
共 50 条
  • [1] Glycolysis and EZH2 boost T cell weaponry against tumors
    Bantug, Glenn R.
    Hess, Christoph
    NATURE IMMUNOLOGY, 2016, 17 (01) : 41 - 42
  • [2] EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion
    Yang, Xiang-Ping
    Jiang, Kan
    Hirahara, Kiyoshi
    Vahedi, Golnaz
    Afzali, Behdad
    Sciume, Giuseppe
    Bonelli, Michael
    Sun, Hong-Wei
    Jankovic, Dragana
    Kanno, Yuka
    Sartorelli, Vittorio
    O'Shea, John J.
    Laurence, Arian
    SCIENTIFIC REPORTS, 2015, 5
  • [3] miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling
    Guo, Yuwen
    Ying, Liang
    Tian, Ye
    Yang, Peiqian
    Zhu, Yichen
    Wang, Zhipeng
    Qiu, Feng
    Lin, Jun
    FEBS JOURNAL, 2013, 280 (18) : 4531 - 4538
  • [4] Effect of siRNA targeting EZH2 on cell viability and apoptosis of bladder cancer T24 cells
    Wang, H. F.
    Yang, H.
    Hu, L. B.
    Lei, Y. H.
    Qin, Y.
    Li, J.
    Bi, C. W.
    Wang, J. S.
    Huo, Q.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) : 9939 - 9950
  • [5] Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader
    Yu, Xufen
    Wang, Jun
    Gong, Weida
    Ma, Anqi
    Shen, Yudao
    Zhang, Chengwei
    Liu, Xijuan
    Cai, Ling
    Liu, Jing
    Wang, Gang Greg
    Jin, Jian
    ONCOGENE, 2023, 42 (13) : 994 - 1009
  • [6] Treating human cancer by targeting EZH2
    Xu, Mengfei
    Xu, Chunyan
    Wang, Rui
    Tang, Qing
    Zhou, Qichun
    Wu, Wanyin
    Wan, Xinliang
    Mo, Handan
    Pan, Jun
    Wang, Sumei
    GENES & DISEASES, 2025, 12 (03)
  • [7] Targeting EZH2 as cancer therapy Comment
    Hanaki, Shunsuke
    Shimada, Midori
    JOURNAL OF BIOCHEMISTRY, 2021, 170 (01) : 1 - 4
  • [8] Regulation of T Cell Differentiation and Function by EZH2
    Karantanos, Theodoros
    Chistofides, Anthos
    Barhdan, Kankana
    Li, Lequn
    Boussiotis, Vassiliki A.
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [9] EZH2 as a Regulator of CD8+T Cell Fate and Function
    Stairiker, Christopher J.
    Thomas, Graham D.
    Salek-Ardakani, Shahram
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [10] EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
    Porazzi, Patrizia
    Nason, Siena
    Yang, Ziqi
    Carturan, Alberto
    Ghilardi, Guido
    Guruprasad, Puneeth
    Patel, Ruchi P.
    Tan, Melody
    Padmanabhan, Anushka Anant
    Lemoine, Jean
    Fardella, Eugenio
    Zhang, Yunlin
    Pajarillo, Raymone
    Chen, Linhui
    Ugwuanyi, Ositadimma
    Markowitz, Kelly
    Delman, Devora
    Angelos, Mathew G.
    Shestova, Olga
    Isshiki, Yusuke
    Blanchard, Tatiana
    Beguelin, Wendy
    Melnick, Ari M.
    Linette, Gerald P.
    Beatty, Gregory L.
    Carreno, Beatriz M.
    Cohen, Ivan J.
    Paruzzo, Luca
    Schuster, Stephen J.
    Ruella, Marco
    CANCER CELL, 2025, 43 (03) : 537 - 551.e7